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Abstract
Background: The incidence and risk factors for diabetic ketoacidosis (diabetic ketoacidosis) and
hyperglycemic hyperosmolar syndrome (hyperglycemic hyperosmolar syndrome, previously called
non-ketotic hyperosmolar coma) have not been reported in a national population of renal
transplant (renal transplantation) recipients.
Methods: We performed a historical cohort study of 39,628 renal transplantation recipients in the
United States Renal Data System between 1 July 1994 and 30 June 1998, followed until 31 Dec
1999. Outcomes were hospitalizations for a primary diagnosis of diabetic ketoacidosis (ICD-9 code
250.1x) and hyperglycemic hyperosmolar syndrome (code 250.2x). Cox Regression analysis was
used to calculate adjusted hazard ratios for time to hospitalization for diabetic ketoacidosis or
hyperglycemic hyperosmolar syndrome.
Results: The incidence of diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome were
33.2/1000 person years (PY) and 2.7/1000 PY respectively for recipients with a prior diagnosis of
diabetes mellitus (DM), and 2.0/1000 PY and 1.1/1000 PY in patients without DM. In Cox
Regression analysis, African Americans (AHR, 2.71, 95 %CI, 1.96–3.75), females, recipients of
cadaver kidneys, patients age 33–44 (vs. >55), more recent year of transplant, and patients with
maintenance TAC (tacrolimus, vs. cyclosporine) had significantly higher risk of diabetic
ketoacidosis. However, the rate of diabetic ketoacidosis decreased more over time in TAC users
than overall. Risk factors for hyperglycemic hyperosmolar syndrome were similar except for the
significance of positive recipient hepatitis C serology and non-significance of female gender. Both
diabetic ketoacidosis (AHR, 2.44, 95% CI, 2.10–2.85, p < 0.0001) and hyperglycemic hyperosmolar
syndrome (AHR 1.87, 95% CI, 1.22–2.88, p = 0.004) were independently associated with increased
mortality.
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Conclusions: We conclude that diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome
were associated with increased risk of mortality and were not uncommon after renal
transplantation. High-risk groups were identified.
Background
Renal transplant recipients are at high risk for post-trans-
plant diabetes mellitus. However, information on the in-
cidence and risk factors for diabetic ketoacidosis (diabetic
ketoacidosis) after solid organ transplantation has been
limited to single-center reports. [1–4] There are even fewer
reports on hyperglycemic hyperosmolar syndrome (hy-
perglycemic hyperosmolar syndrome, previously called
nonketotic hyperosomolar coma) after renal transplanta-
tion. [5,6] Recently, post-transplant diabetes mellitus has
been associated with tacrolimus use in renal transplant re-
cipients with hepatitis C antibody positivity, [7] although
this experience is not universal. [8] Only one report of di-
abetic ketoacidosis associated with tacrolimus use in a pa-
tient without a prior history of diabetes has so far been
reported. [9] Tacrolimus was approved by the FDA for use
in kidney transplantation in 1997. We therefore per-
formed a historical cohort study of the United States Renal
Data System (USRDS) Renal transplant population. Our
objectives were to determine the incidence, risk factors,
and mortality associated with hospitalizations for diabetic
ketoacidosis (primary hospitalization discharge ICD9
code 250.1x) and hyperglycemic hyperosmolar syndrome
(ICD9 code 250.2x) occurring after renal transplantation.
Methods
Patient Population
This study used data from the United States Renal Data
System (USRDS), using standard analysis files (SAF's) as
of May 2000. The USRDS, indirectly mandated by federal
law, incorporates baseline and follow-up demographic
and clinical data on all patients receiving end stage renal
disease (ESRD) therapy in the United States. ESRD thera-
py includes hemodialysis, peritoneal dialysis, and renal
transplantation. Because patient entry into the USRDS is
linked to Medicare reimbursement, and ESRD services are
expensive, very few transplant patients are not represented
in the database. The variables included in the USRDS
standard analysis files (SAF), as well as data collection
methods and validation studies, are listed at the USRDS
website, under 'Researcher's Guide to the USRDS Data-
base', Section E, 'Contents of all the SAF's, http://www.us-
rds.org and published in the USRDS. The demographics
of the renal transplant population have been previously
described (2001 USRDS report). SAF.TXUNOS was used
as the primary dataset, and merged with variables from
SAF.HOSP for hospitalization data, and SAF.PATIENTS
for dates and causes of death as well as causes of renal dis-
ease, as previously reported. [10–12] Patient characteris-
tics and treatment factors were those at the date of
transplant. Recipients of organs other than kidneys were
excluded.
Outcome Definition
We conducted a historical cohort study of the incidence,
risk factors and associated patient survival for hospitalized
cases of diabetic ketoacidosis (based on International
Classification of Diseases-9th Modification Diagnosis
Codes (ICD9) at hospital discharge for diabetic ketoaci-
dosis, 250.1x, and hyperosmotic hyperosmolar syndrome
(also known as non-ketotic hyperosmolar coma), ICD9
code 250.2x, as a primary discharge diagnosis in renal
transplant recipients. The first hospitalization for diabetic
ketoacidosis after the first solitary renal transplant (thus
excluding kidney-pancreas or other multiple transplants)
for a given individual occurring on or after 1 July 1994
and before 1 July 1998 (which included repeat trans-
plants), with follow-up time truncated at three years was
counted in analysis. Hospitalizations were chosen be-
cause they were more accessible in the database and less
subject to interpretation than outpatient cases of diabetic
ketoacidosis, especially since the USRDS database has no
information on confirmatory studies. Hospitalization
data for transplant recipients may be unreliable after the
patient has survived ≥ 3 years post transplant, when hos-
pitalization reporting to Medicare for patients 65 years or
younger is no longer required. However, Medicare report-
ing starts immediately after transplant, regardless of pre-
ceding dialysis status. All hospitalizations with a primary
discharge diagnosis for diabetic ketoacidosis were extract-
ed from SAF.HOSP, merged with the transplant file using
unique identifiers, and hospitalizations outside the range
of the study period were excluded. Hospitalizations for di-
abetic ketoacidosis occurring at any time after renal trans-
plant, including after graft failure (censored for patient
death), were counted in analysis.
Variables used in analysis
The independent associations between patient factors and
hospitalizations for diabetic ketoacidosis were examined
using multivariate analysis with stepwise Cox Regression
including recipient and donor age, recipient race, gender,
weight, pretransplant dialysis (yes/no), duration of dialy-
sis prior to transplantation, total follow-up time, recipient
hepatitis C serology, donor cytomegalovirus serology,
pre-transplant dialysis (yes/no), rejection (either treat-
ment or diagnosis) occurring at any time in the study pe-
riod, induction antibody therapy, maintenanceBMC Endocrine Disorders 2003, 3 http://www.biomedcentral.com/1472-6823/3/1
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immunosuppressive medications at time of discharge af-
ter transplant surgery, graft loss, and cause of end stage re-
nal disease (ESRD, either diabetes or other causes). The
USRDS does not reliably distinguish between type I and
type II diabetes. Previous investigators have used the oc-
currence of diabetes in patients younger than age 40 as a
surrogate for type I diabetes. (13) However, given the
growing frequency of type II diabetes in younger patients,
(14) we did not think this assumption would be valid in
more recent years of the database. We therefore chose to
group all patients with ESRD due to diabetes together. Di-
abetes as a comorbid condition at the time of listing for
transplant was also used as a variable, although informa-
tion on this variable was missing or unknown for 23.3%
of patients (Tables 1,2,3). Information on insulin depend-
ence was missing for 81% of patients, however, and was
not considered reliable for analysis. Episodes of rejection
were not restricted to those occurring in the first year, in
contrast to studies of allograft function, since there is no
evidence that late (vs. early) rejection has a different im-
pact on diabetic ketoacidosis. However, only episodes of
diabetic ketoacidosis or hyperglycemic hyperosmolar syn-
drome occurring after the approximate date of rejection
were used in assessing the association of rejection with di-
abetic ketoacidosis or hyperglycemic hyperosmolar syn-
drome. The total cumulative dose of prednisone was not
Table 1: Rates of Diabetic Ketoacidosis
By Total Hospitalizations
Diabetic ketoacidosis No diabetic ketoacidosis Mean followup (years) Rate per 1000 PY
Diabetes at listingA "Recurrent" 505 7733 1.80 ± 1.11 33.22
No Diabetes at listing "De novo" 84 24,232 1.76 ± 1.07 1.96
By Recipients HospitalizedB
Diabetes at listingA "Recurrent" 244 7733 1.80 ± 1.11 16.99
No Diabetes at listing "De novo" 75 24,232 1.76 ± 1.07 1.75
Numbers and rates (per 1000 person years (PY) of followup) for renal transplant recipients in the US, 1 July 1994–30 June 1998, limited to patients 
with valid information for diabetes as a comorbidity at the time of listing for renal transplantation (A). 23.3% of patients had unknown or missing val-
ues for this variable. Factors associated with missing values for this variable are given in the results section. diabetic ketoacidosis=Primary Hospital 
Discharge Diagnosis for diabetic ketoacidosis during the study period ADiabetes as a comorbid condition at the time of listing for transplant. B No 
duplicate hospitalizations, only one hospitalization per patient "Recurrent" refers to hospitalized diabetic ketoacidosis occurring in patients with a 
known prior diagnosis of diabetes as a comorbid condition. We did not use diabetes as a cause of renal failure to make this distinction, since that 
would most likely underestimate renal transplant recipients who actually had diabetes. "De novo" refers to hospitalized diabetic ketoacidosis occur-
ring in patients WITHOUT a known prior diagnosis of diabetes as a comorbid condition. Patients with medication induced diabetic ketoacidosis of 
hyperglycemic hyperosmolar syndrome would fall into this category.
Table 2: Rates of Non-Ketotic Hyperosmolar Coma
By Total Hospitalizations
Hyperglycemic hyperosmolar 
syndrome
No Hyperglycemic 
hyperosmolar syndrome
Mean followup (years) Rate per 1000 PY
Diabetes at listingA 39 7943 1.80 ± 1.11 2.7
No Diabetes at listing 49 24,259 1.76 ± 1.07 1.1
By Recipients HospitalizedB
Diabetes at listingA 34 7943 1.80 ± 1.11 2.4
No Diabetes at listing 48 24,259 1.76 ± 1.07 1.1
Numbers and rates (per 1000 person years (PY) of followup) for renal transplant recipients in the US, 1 July 1994–30 June 1998. hyperglycemic 
hyperosmolar syndrome=Primary Hospital Discharge Diagnosis for non-ketotic hyperosmolar coma during the study period ADiabetes as a comor-
bid condition at the time of listing for transplant. 23.3% of patients had unknown or missing values for this variable. Factors associated with missing 
values for this variable are given in the results section. B No duplicate hospitalizations, only one hospitalization per patientBMC Endocrine Disorders 2003, 3 http://www.biomedcentral.com/1472-6823/3/1
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available in the USRDS. UNOS tracks the numbers of days
of prednisone administered prior to initial hospital dis-
charge; however, values were missing for >90% of patients
in both databases and could not be used as a covariate in
the above analyses. Maintenance immunosuppressive
medication use, in particular cyclosporine and tacrolimus,
at the time of discharge after transplantation was also an-
alyzed as a preexisting covariate. Information on use of
medications (other than immunosuppressive medica-
tions), alcohol, tobacco, or radiologic procedures was not
available. Dialysis modality was obtained from the file
Sdiabetic ketoacidosis.RXHIST60. The initial dialysis mo-
dality a patient used for at least 60 days after presentation
to end stage renal disease and prior to renal transplanta-
tion was utilized in intention to treat fashion.
Survival Times
For time to diabetic ketoacidosis, survival time was de-
fined as the time from first renal transplant until hospital-
ization for diabetic ketoacidosis, with patients censored at
death, loss to follow-up, or end of the study. Since the
most recent hospitalization date was 31 December, 1999,
this was considered the end of the study period for this
measurement. Survival time was defined as the time from
the date of transplant until the date of death, censored for
loss to follow-up or the end of the study. The end of the
study period was considered April 2000 for this
measurement. The patient survival probabilities were esti-
mated by using the Life Tables and Kaplan Meier method.
Statistical Analysis
All analyses were performed using SPSS 9.0 TM (SPSS,
Inc., Chicago, IL). Files were merged and converted to
SPSS files using DBMS/Copy (Conceptual Software, Hou-
ston, TX). Univariate analysis was performed with Chi-
square testing for categorical variables (Fisher's exact test
was used for violations of Cochran's assumptions) and
Student's two-sided t-test for continuous variables (the
Wilcoxon signed rank test was used for variables without
a Gaussian distribution). Linear regression analysis was
used to assess trends over time, with adjusted residuals in-
spected to verify the appropriateness of the regression
technique. Variables with p < 0.10 in univariate analysis
for a relationship with development of hospitalization for
diabetic ketoacidosis were entered into multivariate anal-
ysis as covariates. Kaplan-Meier analysis was used to con-
struct survival plots of time to hospitalized diabetic
ketoacidosis or hyperglycemic hyperosmolar syndrome
after renal transplantation. Log-log plots were inspected
to assess for proportionality of hazards over time at the
mean of each significant covariate. Because the majority
of patients were censored (did not experience the primary
outcome) during the study period, stepwise Cox Regres-
sion (likelihood ratio method) was used to model factors
associated with time to hospitalized diabetic ketoacidosis
or hyperglycemic hyperosmolar syndrome, controlling for
covariates listed above. For all risk factor analysis reported
in the present study, only the first hospitalization for dia-
betic ketoacidosis or hyperglycemic hyperosmolar syn-
drome, respectively, occurring during the study period
was analyzed (one hospitalization per patient). The asso-
ciation of hospitalized diabetic ketoacidosis or hyperglyc-
emic hyperosmolar syndrome was assessed using Cox
non-proportional hazards regression, with times after
hospitalization for diabetic ketoacidosis coded as 1 and
all other times as 0, as previously reported. [15]
Tacrolimus was introduced into clinical practice more re-
cently than cyclosporine. This could have resulted in bias
due to the shorter potential follow-up for patients taking
cyclosporine, leading to unequal counting of more recent
hospitalizations for diabetic ketoacidosis in patients who
used tacrolimus. In addition, since the rate of diabetic ke-
toacidosis or hyperglycemic hyperosmolar syndrome may
have changed in more recent years of the study, temporal
bias could have arisen despite adjustment for year of
transplant. Therefore, additional analysis was performed
limited to patients who were transplanted on or after 1
January, 1996.
Results
There were 42,096 solitary renal transplant recipients in
the United States Renal Data System transplanted from 1
July 1994 to 30 June 1998, of whom 39,628 had data
complete enough to calculate survival times. The most re-
cent hospitalization date was December 31, 1999. The
most recent date of death was April 2000. Mean follow-up
was 1.89 ± 1.15 years (median, 1.91 years). Of these, 428
recipients were hospitalized with a primary discharge di-
agnosis of diabetic ketoacidosis with 760 total hospitali-
zations. 115 recipients were hospitalized with a primary
discharge diagnosis of hyperglycemic hyperosmolar syn-
drome with 122 total hospitalizations. The most common
secondary discharge diagnosis for both diabetic ketoaci-
dosis and hyperglycemic hyperosmolar syndrome was
kidney replaced by transplant, and secondary diagnoses
did not reveal a preponderance of conditions suggesting
an underlying condition leading to hospitalization. Rates
of diabetic ketoacidosis by history of diabetes at the time
of listing are shown in Table 1. Characteristics of the study
population, as well as risk factors for diabetic ketoacidosis
for the entire cohort and for recipients without a history
of diabetes at the time of listing are shown in Table 2. As
previously reported, the use of tacrolimus rose steadily
during the study period, accounting for 5.2% of all cal-
cineurin inhibitor use in 1994, 5.9% in 1995, 12.1% in
1996, 17.5% in 1997, and 20.3% in 1998. The three-year
incidence of de novo diabetic ketoacidosis was 1.56% in
patients using tacrolimus vs. 0.35% in patients using cy-
closporine. However, there were noteworthy temporalBMC Endocrine Disorders 2003, 3 http://www.biomedcentral.com/1472-6823/3/1
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trends during the time of the study, although none were
statistically significant. As shown in Figure 1, there was an
increase in the rate of both all cases of diabetic ketoacido-
sis and de novo diabetic ketoacidosis during the years of
the study. However, an opposite trend was seen in de
novo diabetic ketoacidosis in tacrolimus users, Figure 2.
As shown, the rate of de novo diabetic ketoacidosis de-
creased sharply among tacrolimus users, while the rate of
total diabetic ketoacidosis did not change. Similar data for
hyperglycemic hyperosmolar syndrome are shown in fig-
ures 3,4. In contrast, there were no clear trends over time,
although rates for the year 1998 appeared disproportion-
ately high.
The mean age of patients hospitalized for diabetic ketoac-
idosis was 41.4 ± 11.1 years vs. 43.4 ± 14.9 years for
recipients not hospitalized for diabetic ketoacidosis, p =
0.006 by student's t-test (equal variances assumed). The
mean BMI of patients hospitalized for hyperglycemic
hyperosmolar syndrome was 24.4 ± 4.5 kg/m2 vs. 25.2 ±
5.3 kg/m2 for recipients not hospitalized for hyperglyc-
emic hyperosmolar syndrome, p = 0.008 by student's t-
test. Of African American recipients, 1.6% were hospital-
ized for diabetic ketoacidosis during the study period vs.
0.8% of recipients of other races (p < 0.001 by Chi
Square), and of patients hospitalized for diabetic ketoaci-
dosis, 37% were African American, vs. 23.1% of patients
Figure 1
Rate of Hospitalizations for Diabetic Ketoacidosis (diabetic ketoacidosis, ICD9 code 250.1x) total and de novo (in patients 
without a history of diabetes as a comorbid condition) over the years of the study. The rate of both total and de novo diabetic 
ketoacidosis increased over time, although these trends were not statistically significant in linear regression analysis.
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not hospitalized for diabetic ketoacidosis (p < 0.001 by
Chi Square).
In Cox Regression analysis, factors that were positively as-
sociated with total rates of hospitalized diabetic ketoaci-
dosis were younger age, graft loss, African American race,
more recent year of transplant, lower body mass index,
and female gender. There were no significant interactions
between race, gender, hepatitis C status, or tacrolimus use.
For de novo diabetic ketoacidosis, gender and graft loss
were not significant, and cadaver donor was significant.
Recipients who used maintenance tacrolimus (adjusted
hazard ratio, 2.27, 95% confidence interval, 1.52–3.38, p
= 0.001) had a higher risk of de novo diabetic ketoacido-
sis, compared to recipients who used cyclosporine. Signif-
icance persisted even in analysis limited to patients who
were transplanted on or after 1 Jan 1996 (adjusted hazard
ratio for tacrolimus, 1.75, 95% confidence interval, 1.06–
2.89, p = 0.03). However, the pattern of risk over time vi-
olated the proportional hazards assumption, since there
was a substantially greater risk of de novo diabetic ketoac-
idosis among tacrolimus users starting at two years after
transplant, coinciding with the introduction of tacrolimus
into clinical practice. Therefore, analysis was also per-
formed limited to patients transplanted on or after 1 July
1996, limited to two years of follow-up. In this analysis,
Figure 2
Rate of Hospitalizations for Diabetic Ketoacidosis (diabetic ketoacidosis, ICD9 code 250.1x) total and de novo (in patients 
without a history of diabetes as a comorbid condition) over the years of the study, limited to patients with baseline tacrolimus 
use. There was a marked decrease in de novo diabetic ketoacidosis over time in this group (p = 0.13 by linear regression), 
with no significant trend over time for total diabetic ketoacidosis.
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tacrolimus was not significantly associated with de novo
diabetic ketoacidosis, p = 0.10, adjusted hazard ratio,
2.11, 95% CI, 0.86–5.21. In analysis including patients
with diabetes during the entire study period, tacrolimus
use was only significantly associated with diabetic ketoac-
idosis in recipients of cadaver kidneys (adjusted hazard ra-
tio, 2.15, 95% CI, 1.10–4.23, p = 0.03).
The mean age of patients hospitalized for hyperglycemic
hyperosmolar syndrome was 46.2 ± 13.0 years vs. 43.4 ±
14.9 years for recipients not hospitalized for hyperglyc-
emic hyperosmolar syndrome, p = 0.04 by student's t-test
(equal variances assumed). The mean BMI of patients
hospitalized for hyperglycemic hyperosmolar syndrome
was 26.6 ± 4.9 kg/m2 vs. 25.2 ± 5.3 kg/m2 for recipients
not hospitalized for hyperglycemic hyperosmolar syn-
drome, p = 0.03 by student's t-test. Of recipients who were
seropositive for hepatitis C, 0.8% were hospitalized for
hyperglycemic hyperosmolar syndrome during the study
period vs. 0.2% of HCV negative recipients (p < 0.001 by
Chi Square), and of patients hospitalized for hyperglyc-
emic hyperosmolar syndrome, 16.5% were HCV positive,
vs. 5.7% of patients not hospitalized for hyperglycemic
hyperosmolar syndrome (p < 0.001 by Chi Square). Of Af-
rican American recipients, 0.7% were hospitalized for hy-
perglycemic hyperosmolar syndrome during the study
Figure 3
Rate of Hospitalizations for Hyperosmolar Hyperglycemic syndrome (hyperglycemic hyperosmolar syndrome), also known as 
Nonketotic hyperosmolar coma (NKHC, ICD9 code 250.2x) total and de novo (in patients without a history of diabetes as a 
comorbid condition) over the years of the study, entire study cohort. Results are linear regression are not shown due to lack 
of significance, although the year 1998 may be an outlier.
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period vs. 0.1% of recipients of other races (p < 0.001 by
Chi Square), and of patients hospitalized for hyperglyc-
emic hyperosmolar syndrome, 60% were African Ameri-
can, vs. 23.1% of patients not hospitalized for
hyperglycemic hyperosmolar syndrome (p < 0.001 by Chi
Square). There was considerable overlap between risk fac-
tors for diabetic ketoacidosis and hyperglycemic hyperos-
molar syndrome except for the significance of recipient
hepatitis C positive serology and the lack of significance of
female gender (Table 4). There was no significant interac-
tion between recipient hepatitis C serology and tac-
rolimus use. There was no association between
hyperglycemic hyperosmolar syndrome and BMI, either
as a continuous or as a categorical variable. No independ-
ent risk factors for de novo hyperglycemic hyperosmolar
syndrome were identified, and are therefore not presented
in tabular form.
In-hospital mortality was 1.9% for patients with diabetic
ketoacidosis and 0.9% for patients with hyperglycemic
hyperosmolar syndrome. Mortality after diabetic
ketoacidosis is shown in Figure 5. The risk of mortality af-
ter hospitalization for diabetic ketoacidosis was fairly
constant over time. Hospitalized diabetic ketoacidosis
was independently associated with increased mortality in
Cox non-proportional hazards regression analysis, adjust-
ed hazard ratio = 2.44, 95% CI, 2.10–2.85, p < 0.0001.
Causes of death were missing or unknown for 57.3% of
Figure 4
Rate of Hospitalizations for hyperglycemic hyperosmolar syndrome (code 250.2x) total and de novo (in patients without a his-
tory of diabetes as a comorbid condition) over the years of the study, limited to patients with baseline tacrolimus use.
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patients with diabetic ketoacidosis. The leading specified
causes of death were cardiac arrest of unknown cause
(8.5%), acute myocardial infraction (5%), sepsis (4%),
and atherosclerotic heart disease (4%).
Similar to the linear risk of mortality after diabetic ketoac-
idosis, the risk of mortality after hyperglycemic hyperos-
molar syndrome was constant over time (Figure 6).
Hospitalization for hyperglycemic hyperosmolar syn-
drome was independently associated with increased mor-
tality in Cox non-proportional hazards regression
analysis, adjusted hazard ratio = 1.87, 95% CI, 1.22–2.88,
p = 0.004. Causes of death were missing or unknown for
45.5% of patients with hyperglycemic hyperosmolar syn-
drome. The leading cause of death in patients hospitalized
for hyperglycemic hyperosmolar syndrome was acute my-
ocardial infarction (18%), cardiac arrest of unknown
cause (13%), and sepsis (9%).
Discussion
The present study showed that renal transplant recipients
had a rate of diabetic ketoacidosis of 33.2/1000 person
years in recipients a history of diabetes as a comorbid
condition and 1.9/1000 person years in patients without
a prior history of diabetes (measured as total
hospitalizations for comparison with other reports). In
Figure 5
Mortality after hospitalization for diabetic ketoacidosis (diabetic ketoacidosis). diabetic ketoacidosis was associated with a sig-
nificantly increased risk of mortality after renal transplantation and was fairly constant over time. diabetic ketoacidosis was 
independently associated with mortality compared to renal transplant recipients who did not have diabetic ketoacidosis (by 
Cox non-proportional hazards regression analysis, adjusted hazard ratio = 2.44, 95% CI, 2.10–2.85, p < 0.0001).
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contrast, the estimated annual incidence of diabetic ke-
toacidosis in the general population was 4.6–8 episodes
per 1000 diabetic subjects. [16] In the general population,
the rate of diabetic ketoacidosis episodes as a primary hos-
pitalization diagnosis was 0.3/1000 patients, and the rate
of hyperglycemic hyperosmolar syndrome episodes was
0.04/1000 in 1997 (rates stratified for patients with diabe-
tes were not available). [17] Although statistical compari-
son could not be performed due to the much higher rate
of diabetes among renal transplant recipients than in the
general population, the rates of diabetic ketoacidosis and
hyperglycemic hyperosmolar syndrome in renal trans-
plant recipients appear to be substantially higher than for
either diabetic patients or for the general population, after
excluding patients with combined kidney-pancreas
transplants.
Certain risk factors were common to both the total risk of
diabetic ketoacidosis and the risk of de novo diabetic ke-
toacidosis (diabetic ketoacidosis occurring in patients
without a prior known history of diabetes). Consistent
with the general population, African Americans were at
higher risk of diabetic ketoacidosis than non-African
Americans (Hispanic race was only introduced into the
database recently). [18–21] The higher risk of African
Americans was independent of other factors in the
database, such as body mass index, graft loss, rejection ep-
isodes or employment status. Despite adjustment for
these factors, socioeconomic factors could certainly not be
excluded, and have been implicated in prior studies. Sim-
ilarly, low body mass index was associated with diabetic
ketoacidosis in either situation (in contrast to the
association of high body mass with the increased risk of
type II diabetes). [22] However, differences in gender and
Table 3: Categorical variables of renal transplant recipients, 1 July 1994–30 June 1998A
Factor Renal Transplant recipients Missing, N (%)
N with valid Followup times
Male Recipient (female) 23,827 (60.1) 0
African American (all other races) 9142 (23.1) 640 (1.5)
Graft lossB (Absent) 2815 (6.5%) 0
Cadaveric Donor (living donor) 27,369 (69.1) 0
Quartiles of Age (vs. >55 years)
<33
33–44
45–55
Diabetes as a comorbidity at listing (vs. absent) 7977 (24.7) 9931 (23.3)
History of Peritoneal Dialysis (vs. Hemodialysis) 8260 (19.6) 7855 (18.7)
Recipient HCV Positive (Yes/No) 2198 (5.6) 5743 (13.6)
Donor CMV Positive (Yes/No) 23,552 (57.1) 1620 (3.8)
Pretransplant dialysis (Yes/No) 31,046 (86) 284 (0.8)
Rejection (Yes/No) 8335 (19.8) 0
Cause of ESRD (vs. all others)
Diabetes 7862 (19.7) 5178 (12.3%)
Hypertension 5495 (13.2) 5178 (12.3%)
Maintenance Medications
Cyclosporine (vs. Tacrolimus) 31,448 (74.7) 3372 (8)
Tacrolimus (vs. Cyclosporine) 4623 (11.9) 3372 (8)
Mycophenolate (vs. Azathioprine) 18,608 (47.9) 3221 (7.6)
Azathioprine (vs. Mycophenolate) 16,308 (41.9) 3157 (7.5)
Prednisone (vs. all others) 34,451 (90.1) 3880 (9.2)
Induction Antibody Therapy 11,905 (28.3) 2277 (5.4)
Employment Status
Working Full time 14,714
Working Part time by choice 858
Working Part time due to disease 2012
Working part time reason unknown 200
Not working 13,833
Retired 2940
Missing or unknown 7539
Data given as the number (% of total) mean ± one standard deviation A = followup time truncated at three years post transplant ESRD = end-stage 
renal disease B = time-dependent variableBMC Endocrine Disorders 2003, 3 http://www.biomedcentral.com/1472-6823/3/1
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graft loss were not associated with de novo diabetic ke-
toacidosis. Each of these may reflect risk factors for diabe-
tes in the general population. Conversely, donor type and
use of maintenance tacrolimus were only associated with
de novo diabetic ketoacidosis. The increased risk of
cadaver donor type could be related to medication use.
The relatively high rate of "de novo" diabetic ketoacidosis
(diabetic ketoacidosis occurring in patients who did not
have a known diagnosis of diabetes at the time of trans-
plant) could represent drug-associated diabetic ketoacido-
sis, which has infrequently been reported with the use of
both tacrolimus and cyclosporine. [3] Previous case series
did not have sufficient sample size to determine compet-
ing risks between calcineurin inhibitors, but the present
study would suggest the risk is greater with tacrolimus.
Because of rapid changes in the use of tacrolimus during
the study period, as indicated above, conclusions should
be limited. We would certainly caution any interpretation
of tacrolimus use since there were substantial temporal
trends during the study, and tacrolimus was not approved
by the FDA for use in kidney transplantation until 1997.
As indicated, in our analysis limited to that time span, tac-
rolimus was not significantly associated with increased
risk of diabetic ketoacidosis.
Figure 6
Mortality after hospitalization for hyperglycemic hyperosmolar syndrome. hyperglycemic hyperosmolar syndrome was associ-
ated with a significantly increased risk of mortality after renal transplantation (by Cox non-proportional hazards regression 
analysis, adjusted hazard ratio = 1.87, 95% CI, 1.22–2.88, p < 0.004). The risk of mortality after NKHC was roughly constant 
over time.
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Almost all reports of post-transplant diabetes mellitus in
the medical literature have either concerned type II
diabetes or have not specified by type. Therefore, reported
risk factors such as obesity, cumulative prednisone use,
and hepatitis C status would not be expected to affect the
risk of diabetic ketoacidosis, consistent with reports in the
general population. This is in contrast to hyperglycemic
hyperosmolar syndrome, which would be expected to
occur disproportionately in patients with type II diabetes.
While older age and higher BMI were significant in univar-
iate analysis, they were not significant in multivariate
analysis, while the significance of positive recipient hepa-
titis C serology persisted. Use of diabetes as an aggregate
outcome, combining either both type I and type II diabe-
tes, or combining diabetic ketoacidosis and hyperglyc-
emic hyperosmolar syndrome, might obscure the
relationship with certain risk factors if the associations
were in different directions (as is the case with body mass
index, for example: low body mass index being associated
with type I diabetes, and high body mass being associated
with type II diabetes). Use of such aggregate outcomes
might also have missed an association between hypergly-
cemic hyperosmolar syndrome and hepatitis C. The
present study thus provides more indirect evidence that
the post-transplant diabetes associated with hepatitis C
infection is predominantly type II diabetes, as suggested
in other reports. [23,24] This is in contrast to a lack of as-
sociation between hepatitis C seropositivity and diabetes
as a cause of renal failure, as we have previously reported.
[25]
Nevertheless, the increasing rate of diabetic ketoacidosis
noted during the study period (Figure 1, more marked for
total diabetic ketoacidosis than de novo diabetic ketoaci-
dosis) is in contrast to the decreasing rate of de novo
diabetic ketoacidosis and stable rate of total diabetic ke-
toacidosis noted for users of tacrolimus (Figure 2). While
this information is necessarily preliminary, it suggests the
possibility that factors other than tacrolimus use may be
responsible for the increasing rate of diabetic ketoacidosis
noted during the study, which was independent of all oth-
er factors assessed. We did not find an association be-
tween diabetic ketoacidosis and viral infections other than
hepatitis C, notably cytomegalovirus, nor did we find an
association between diabetic ketoacidosis and antibody
induction therapy, which would be expected to decrease
immunity but might also allow for a greater propensity to
viral infections. We can only point to another recent re-
port by Bhalla et al, [26] which found that "de novo" post-
transplant diabetes mellitus (confirmed by renal biopsy)
was much more common and much more rapid in onset
than previously suspected, and could not be explained by
usual clinical predictors, which is quite similar to our
findings. The authors implicated "novel mechanisms" as
the reason for this rapid increase. Whether this represents
a relationship with newly appreciated viral infections,
such as polyomavirus, or other factors is presently
unknown.
Both diabetic ketoacidosis and hyperglycemic hyperos-
molar syndrome were associated with an increased risk of
mortality among renal transplant recipients, consistent
with reports in the general population. [27,28] If any-
thing, the relative risk associated with diabetic ketoacido-
sis was greater than that for hyperglycemic hyperosmolar
syndrome, somewhat in contrast to the general popula-
tion. However, previous population based reports have
not adjusted for the difference in age of presentation for
this differing conditions. Given the limitations of the da-
tabase, causes of death were primarily cardiovascular and
not infectious, also consistent with the general popula-
tion. [16]
There are several limitations to this retrospective study.
Findings are associative, not causative, and risk cannot be
assigned without the ability to control for other variables
prospectively during the course of the study. We could not
assess the causes for hospitalization for diabetic ketoaci-
dosis or hyperglycemic hyperosmolar syndrome, or how
they were treated, including the use of insulin. This study
could not independently verify the type of diabetes. We
could not assess certain important risk factors, such as nu-
tritional status, the use of alcohol or infection, with
hospitalized diabetic ketoacidosis or hyperglycemic
hyperosmolar syndrome. However, ICD-9 coding for de-
termining rates of medical conditions has been used in
other published studies, [29] as well as the National
Center for Health Statistics. http://www.cdc.gov/nchs The
current study's limitation to hospitalized cases of diabetic
ketoacidosis and hyperglycemic hyperosmolar syndrome
would tend to underestimate the frequency of these con-
ditions in this population. However, these conditions are
almost universally managed by hospitalization in the
United States. Another limitation of the study is the ina-
bility to track whether the patients were subsequently
switched from tacrolimus or cyclosporine during the
course of the present study. However, reports of conver-
sion from cyclosporine to tacrolimus, [30,31] which are
most commonly employed as a rescue agent for refractory
acute or chronic rejection or cyclosporine toxicity, suggest
that this number is very small. Similarly, conversion from
tacrolimus to cyclosporine, most commonly due to tac-
rolimus induced diabetes, by published report appears to
be even rarer. [32] The short followup duration of the
study may also be a limitation. Strengths of the present
analysis include its large size and population-based char-
acter, and relatively complete capture and followup.
In conclusion, rates of diabetic ketoacidosis and hypergly-
cemic hyperosmolar syndrome after renal transplantationBMC Endocrine Disorders 2003, 3 http://www.biomedcentral.com/1472-6823/3/1
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were substantially higher than reported for the general
population, whether in diabetic or non-diabetic popula-
tions. These rates appear to be increasing significantly
over time, particularly for diabetic ketoacidosis, even as
the risk for diabetic ketoacidosis in patients treated with
tacrolimus is decreasing significantly. In addition, we
identified high-risk groups for diabetic ketoacidosis, de
novo diabetic ketoacidosis and hyperglycemic
hyperosmolar syndrome after renal transplantation, and
confirmed the association of both diabetic ketoacidosis
and hyperglycemic hyperosmolar syndrome with in-
creased mortality after renal transplantation.
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